Sun BioPharma, Inc. (OTCMKTS:SNBP) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07 Submission of Matters to a Vote of Security Holders.
The 2018 Annual Meeting of Shareholders of Sun BioPharma, Inc. (the “Company”) was held on May 22, 2018. The final results of the shareholder vote on each proposal brought before the Annual Meeting were as follows:
|
For |
Withhold |
Broker Non-Votes |
||
|
Proposal No. 1—Election of class IIdirectors |
||||
|
Michael T. Cullen, M.D., M.B.A. |
2,637,476 |
2,857 |
|
|
|
D. Robert Schemel |
2,612,333 |
28,000 |
|
|
|
For |
Against |
Abstain |
Broker Non-Votes |
|
|
Proposal No. 2—Ratification of the selection of Cherry Bekaert LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018. |
2,850,939 |
|
|
|
All proposals were approved by the Company’s shareholders by the required vote.
About Sun BioPharma, Inc. (OTCMKTS:SNBP)
Sun BioPharma, Inc., formerly Cimarron Medical, Inc., is a clinical stage drug development company. The Company is a biopharmaceutical company focused on developing therapies for pancreatic diseases. It is engaged in the commercial development of a polyamine analogue for pancreatic cancer and for a second indication in chronic pancreatitis. The Company’s products include SBP-101, SBP-102 and SBP-103. Its SBP-101 is a polyamine compound and exhibits specificity for the exocrine pancreas, with therapeutic potential for both pancreatic cancer and pancreatitis indications. It develops SBP-101 for the treatment of patients with pancreatic ductal adenocarcinoma. The SBP-102 product is in non-clinical feasibility evaluation for the treatment of patients with pancreatitis. The SBP-103 product is in non-clinical exploratory evaluation. The Company has enrolled first patient in its Phase I clinical trial of SBP-101 in patients with previously treated pancreatic cancer.
